Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Reduced by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 38.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,417 shares of the medical equipment provider's stock after selling 6,380 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Hologic were worth $643,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HOLX. West Financial Advisors LLC acquired a new position in shares of Hologic during the first quarter valued at $50,000. Czech National Bank lifted its position in Hologic by 2.3% in the 1st quarter. Czech National Bank now owns 51,538 shares of the medical equipment provider's stock valued at $3,184,000 after purchasing an additional 1,176 shares during the last quarter. Rhumbline Advisers boosted its stake in Hologic by 5.1% during the 1st quarter. Rhumbline Advisers now owns 535,348 shares of the medical equipment provider's stock valued at $33,068,000 after purchasing an additional 25,822 shares during the period. GAMMA Investing LLC raised its stake in Hologic by 4,467.2% during the 1st quarter. GAMMA Investing LLC now owns 195,749 shares of the medical equipment provider's stock valued at $120,910,000 after acquiring an additional 191,463 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in Hologic by 1,864.3% during the 1st quarter. Versant Capital Management Inc now owns 1,375 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 1,305 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HOLX. Raymond James reissued an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Evercore ISI reduced their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $77.42.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.88% of the company's stock.

Hologic Trading Up 0.4%

Shares of Hologic stock traded up $0.24 on Monday, reaching $64.57. 2,234,230 shares of the company were exchanged, compared to its average volume of 2,295,763. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The firm has a market capitalization of $14.39 billion, a price-to-earnings ratio of 20.37, a price-to-earnings-growth ratio of 2.14 and a beta of 0.55. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a fifty day moving average price of $58.27 and a 200-day moving average price of $65.26.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter last year, the business posted $1.03 EPS. Hologic's revenue was down 1.2% on a year-over-year basis. On average, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.